Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00299052 · ClinicalTrials.gov registry record · Phase 4

Efficacy of DBM on Fractures of the Shinbone (Tibia)

A Phase 4 study, sponsored by Emory University.

Completed
Registry status
Phase 4
Development phase
16
Enrollment target

NCT00299052 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00299052, a Phase 4 study, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 4
Development phase
16 participants
Enrollment target

Study Summary

The Tibia bone (shinbone) is located in the leg, itis the most frequently fractured bone in the body and has very poor blood supply because it is surrounded by skin and fat instead of muscle like the thighbone causing healing problems. Problems frequently found during the healing process are malunion (bone heals in the wrong place), nonunion (the bone never heals), and compartment syndrome (a big inflammation of muscle that causes compression of nerves and blood vessels) with necrosis (death) of tissue. Surgeons have tried to decrease these problems by using different surgical techniques and substances to accelerate healing. Substances frequently used in fractures are bone grafts. Bone grafts are normally obtained from the wrist or the hip bone, and sometimes can cause other complications varying from pain to infection. To avoid complications, investigators have used alternatives such as obtaining bone from donors. The donor bone grafts are carefully analyzed and cleaned to ensure they will not cause problems for the receiver. Bone obtained from donors is called Demineralized Bone Matrix (DBM). DBM has proved to be very effective in helping fractures to heal faster and we want to use it in patients with tibia fractures. This study is important because DBM can improve the way tibia fractures are treated and could have the potential to decrease the time patients must stay in the hospital. DBM could improve healing time and diminish overall costs. Also, with the use of DBM plus reamings, patients will have fewer complications like pain and infection.

Interventions

  • DEVICE Grafton DBM
  • BIOLOGICAL Reamings

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2006-03
Est. Completion 2008-09
Phase Phase 4

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT00299052

The ClinicalTrials.gov registry entry for NCT00299052 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Grafton DBM is the first listed.

NCT00299052 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00299052 about?

NCT00299052 is a clinical study titled "Efficacy of DBM on Fractures of the Shinbone (Tibia)". The Tibia bone (shinbone) is located in the leg, itis the most frequently fractured bone in the body and has very poor blood supply because it is surrounded by skin and fat instead of muscle like the thighbone causing healing problems. Problems frequently found during the healing process are malunio...

What is the current status of trial NCT00299052?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2006-03. Estimated completion is 2008-09.

What interventions are being tested in trial NCT00299052?

The interventions under investigation include: Grafton DBM (DEVICE), Reamings (BIOLOGICAL).

Who is sponsoring clinical trial NCT00299052?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.